Juniper Publishers- Surgery| Dental Implant Placement without Grafting in a Young Patient with a Large Cyst Defect


Authored by Çağrı Akçay,
Odontogenic cysts are the most common form of cystic lesions that affect the maxillofacial region. After removal of cysts, large defects can occur in the cyst region. Due to occurence of large defects before dental implantation different grafting methods should be used to make the bone adequate for implant operation. The purpose of this study is to show the healing of bone defects in young patients without grafting is unexpectedly as well as grafted defects.

Odontogenic cysts are the most common form of cystic lesions that affect the maxillofacial region. 60% of all jaw cysts are radicular or residual cysts [1-3]. Patients in their second and third decades of life are affected most commonly. Radicular cysts can occur in the periapical area of any teeth, at any age but are seldom seen associated with the primary dentition [4]. The most frequent cyst of the teeth bearing areas is the radicular, also called periapical or apical cyst. Radicular cyst arise from the proliferation of the epithelial remnants of Malassez rest in response to stimulation of chronic inflammatory processes in the apical region of the necrotic tooth. This cyst is classified as inflammatory, because in the majority of cases it is a consequence to pulpalnecrosis following caries, with an associated periapical inflammatory response [3-6]. Dental implants require sufficient bone to be adequately stabilised. Augmentation grafting adds strenght to an extremely deficient maxilla and improves the height and contour of the available bone for implant placement on the denture-bearing areas. However in young patients bone healing is suprisingly as good as grafting. The purpose of this study is to show the healing of bone defects in young patients without grafting is unexpectedly as well as grafted defects.

To view more… Full Text
To know more about our journal Surgery Journals
To know more about our open access journals 

Comments

Post a Comment

Popular posts from this blog

Juniper Publishers| The Anatomical Architecture of the Junction between the Great Cerebral Vein and the Straight Sinus in Correlation to the Physiological and Biochemical Impact on Multiple Sclerosis Subtypes and Disease Progression- A Review Article

Image
  Journal of Surgery -  JuniperPublishers Abstract Introduction:  Multiple Sclerosis (MS) is a debilitating autoimmune disorder, characterized by damage to the white matter of the central nervous system. Studies suggest a relationship between impaired cerebral venous blood flow and progressive destruction of white matter in the CNS. Altered cerebral venous architecture is a possible mechanism that may contribute to a compromised venous blood flow pattern in MS patients. Natural variations at junction located between the great cerebral vein (GCV) and the straight sinus (Ss) located within the cerebral venous drainage system can potentially exacerbate MS progression. Recent data indicates that abnormal cerebral venous hemodynamics contributes to the pathophysiology observed in MS through an unknown mechanism that increases hydraulic resistance. Objective:  This review aims to investigate if anatomical variations at the GSV and Ss junction elicit a profound effect on the cerebral venous s
Read more

Juniper Publishers| The Use of the Second-Generation Protein Kinase Inhibitors in Patients with Gastrointestinal Stromal Tumor with Failure to the Treatment with Imatinib

  Journal of Surgery -  JuniperPublishers Introduction:  Gastrointestinal Stromal Tumor (GIST) is considered the most common mesenchymal tumor of the gastrointestinal tract. Approximately 85% of GISTs have mutations in proto-oncogene KIT encoding, a tyrosine kinase receptor. About 8% of GISTs are associated to mutations in the growth factor receptor alpha (PDGFRA) gene. The standard treatment of GIST is the surgical resection of the tumor. In cases of metastasis and tumor recurrence specific drugs as tyrosine kinase inhibitors are used. The first line treatment is Imatinib. Although the treatment with imatinib failed in some patients for the metastatic and relapsed treatment of GIST, the patients can to use other drugs, called second generation. Discussion:  One of the great advances in the diagnosis of GIST was the recognition through the immunohistochemistry of the c-Kit marker. The tyrosine kinase inhibitor, imatinib, has become the standard treatment for those, with high-risk resec
Read more